Fate Therapeutics Inc

Market cap: $2,964,580,328

Exchange: NAS

Sector: Health Technology

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

STOCK PRICE CHART

Key Statistics

Company Name

Fate Therapeutics Inc

Average Volume (10 days)

1,201,819

Average Volume (30 days)

1,549,191

Moving Average (50 days)

$25.12

Moving Average (200 days)

$32.88

Ex-Divided Date

n/a

Dividend Yield

0

P/E Ratio

-12.7371

Market Cap

2,964,580,328

Shares Outstanding

96,629,085

52-Week High Split Adjust Only

97.43

52-Week Low Split Adjust Only

17.1

Employee Count

279

Beta

2.0831

Next Earnings Date

2022-08-03

TTM Dividend Rate Per Share

0

Price Changes

Past 5 days

0.08%

Past 30 days

0.46%

Past 3 months

-0.14%

Past 6 months

-0.24%

Past year

-0.61%

Past 2 years

-0.11%

Past 5 years

9.06%

Max % Change

3.63%

PEER GROUP COMPARATIVE PERFORMANCE

NameTickerPrice/Sales (ttm)Price/Book (ttm)Forward P/EPEG RatioEV/Revenue
Fate Therapeutics IncFATEn/an/a-34.4n/an/a
Peer AvgN/A5.886.229.05.885.44
Becton, Dickinson And Co.BDX3.732.8318.83.734.47
Neurocrine Biosciences, Inc.NBIX8.707.5544.78.708.17
Sarepta Therapeutics IncSRPT10.5311.27-10.810.539.40
PTC Therapeutics IncPTCT6.439.46n/a6.435.18
Avidity Biosciences IncRNAn/an/a-7.7n/an/a